INSIGHTS – Cadence

By Sugata Biswas In Communications

Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business

For the third time in our ten-year history, Cadence Communications & Research has been listed on Inc. Magazine’s “Inc. 5000,”…

Read More

For the 3rd Time, Women-Owned Cadence Communications & Research Appears on the Inc. 5000, Ranking No. 3160 With Three-Year Revenue Growth of 116%

Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies

FEATURED INSIGHTS Medical Communications Oncology Updates White Papers

White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer

By Zachary Moore | FEATURED INSIGHTS, Medical Communications, Oncology Updates, White Papers

Approval Blog Medical Communications Oncology Updates

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates

Market Access Market Research Oncology Updates

Take a Look Into Our Market Access Work

By Cadence Team | Market Access, Market Research, Oncology Updates

Market Access Market Research Oncology Updates

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

By Cadence Team | Market Access, Market Research, Oncology Updates

Communications

Act NOW!

By Cadence Team | Communications

ALL CADENCE INSIGHTS

Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business

Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies

White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer

Client Testimonials

Clinical Case Forum

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

Take a Look Into Our Market Access Work

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

Act NOW!

Tips on Cultivating Vision in your Organization

Reflections on the Legacy of Dick Fordyce

Starbucks, Pumpkin Spice Latte and Why Medical Myths Persist in the Age of Information

The Cadence Concierge Experience

Meeting Planning Processes 101’s

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

What Does it Mean for a Vendor to be of Service?

Leveraging Innovation Centers to Re-prime the Development Pump!

What are the biggest concerns manufacturers have about the Sunshine Act?

Will the Sunshine Act eliminate bias from the US healthcare system?

Mixology…Blending Methodologies for Today’s Challenges

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL

Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML

Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy

Founder’s Blog: Why You Should Give a Damn about Your Vendor’s Culture

Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer

Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer

Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors

Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer

Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC

What can the Pharmaceutical industry do to re-prime its development pump?

Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution

How do we mix qualitative insight with quantitative research?

Why Cadence Achieved Status as One of Inc.’s Fastest-Growing Private Companies for Second Year in a Row!

The Forward March of Regress

What will be the impact of the ACA on cancer treatment?

Advice from Founder of Cadence Research, One of Inc.’s Fastest-Growing Private Companies in 2012